J Korean Med Sci.  2024 Jan;39(2):e6. 10.3346/jkms.2024.39.e6.

COVID-19 Mortality and Severity in Cancer Patients and Cancer Survivors

• Park JM
• Koo HY
• Lee Jr
• Lee H
• Lee JY

• KMID: 2550806
• DOI: http://doi.org/10.3346/jkms.2024.39.e6

Abstract

Background
We aimed to investigate mortality, severity, and risk of hospitalization in coronavirus disease 2019 (COVID-19) patients with cancer.
Methods
Data of all patients aged 40–79 years from the Korean Disease Control and Prevention Agency-COVID19-National Health Insurance Service who were diagnosed with COVID-19 between January 1, 2020 and March 31, 2022, in Korea were included. After 1:1 propensity score matching, 397,050 patients with cancer and 397,050 patients without cancer were enrolled in the main analysis. A cancer survivor was defined as a patient who had survived 5 or more years since the diagnosis of cancer. Multiple logistic regression analysis was performed to compare the risk of COVID-19 according to the diagnosis of cancer and time since diagnosis.
Results
Cancer, old age, male sex, incomplete vaccination against COVID-19, lower economic status, and a higher Charlson comorbidity index were associated with an increased risk of hospitalization, hospitalization with severe state, and death. Compared to patients without cancer, the adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for hospitalization, hospitalization with severe state, and death in patients with cancer were 1.09 (1.08–1.11), 1.17 (1.11–1.24), and 1.94 (1.84–2.05), respectively. Compared to patients without cancer, the ORs (95% CIs) for hospitalization in cancer survivors, patients with cancer diagnosed 2–5 years, 1–2 years, and < 1 year ago were 0.96 (0.94–0.98), 1.10 (1.07–1.13), 1.30 (1.25–1.34), and 1.82 (1.77–1.87), respectively; the ORs (95% CIs) for hospitalization for severe disease among these patients were 0.90 (0.85–0.97), 1.22 (1.12–1.32), 1.60 (1.43–1.79), and 2.29 (2.09–2.50), respectively.
Conclusion
The risks of death, severe state, and hospitalization due to COVID-19 were higher in patients with cancer than in those without; the more recent the diagnosis, the higher the aforementioned risks. Cancer survivors had a lower risk of hospitalization and hospitalization with severe disease than those without cancer.

Keyword

COVID-19; Cancer; Cancer Survivors; Mortality; Severity

Reference

1. Costa GJ, de Azevedo CRAS, Júnior JIC, Bergmann A, Thuler LCS. Higher severity and risk of in-hospital mortality for COVID-19 patients with cancer during the year 2020 in Brazil: a countrywide analysis of secondary data. Cancer. 2021; 127(22):4240–4248. PMID: 34343344.

2. de Azambuja E, Brandão M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, et al. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. ESMO Open. 2020; 5(5):e000947. PMID: 32978251.

3. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3):335–337. PMID: 32066541.

4. Yürekli A, Erbaş O. Cancer and immunosuppression. J Exp Basic Med Sci. 2021; 2(2):116–121.

5. Zhang Y, Rajput A, Jin N, Wang J. Mechanisms of immunosuppression in colorectal cancer. Cancers (Basel). 2020; 12(12):3850. PMID: 33419310.

6. Oh SE, Choi MG, Seo JM, An JY, Lee JH, Sohn TS, et al. Prognostic significance of perioperative nutritional parameters in patients with gastric cancer. Clin Nutr. 2019; 38(2):870–876. PMID: 29503057.

7. Jeong W, Park EC, Nam CM, Park S, Nam JY, Jang SI. Health behavior changes and mortality among South Korean cancer survivors. Sci Rep. 2022; 12(1):16011. PMID: 36163240.

8. Johnson C, Krakow M, Patel V. Access and Use of Electronic Health Information by Individuals with Cancer: 2017–2018. Washington, D.C., USA: Office of the National Coordinator for Health Information Technology;2020.

9. Marzorati C, Riva S, Pravettoni G. Who is a cancer survivor? A systematic review of published definitions. J Cancer Educ. 2017; 32(2):228–237. PMID: 26854084.

10. Chopra I, Kamal KM. A systematic review of quality of life instruments in long-term breast cancer survivors. Health Qual Life Outcomes. 2012; 10(1):14. PMID: 22289425.

11. Lee JW, Yeo Y, Ju HY, Cho HW, Yoo KH, Sung KW, et al. Current status and physicians’ perspectives of childhood cancer survivorship in Korea: a nationwide survey of pediatric hematologists/oncologists. J Korean Med Sci. 2023; 38(29):e230. PMID: 37489718.

12. Lee JE, Shin DW, Lee H, Son KY, Kim WJ, Suh YS, et al. One-year experience managing a cancer survivorship clinic using a shared-care model for gastric cancer survivors in Korea. J Korean Med Sci. 2016; 31(6):859–865. PMID: 27247493.

13. Bober SL, Recklitis CJ, Campbell EG, Park ER, Kutner JS, Najita JS, et al. Caring for cancer survivors: a survey of primary care physicians. Cancer. 2009; 115(18):Suppl. 4409–4418. PMID: 19731354.

14. Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017; 46(3):799–800. PMID: 27794523.

15. Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson comorbidity index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019; 12(4):188–197. PMID: 31428236.

16. World Health Organization. COVID-19 therapeutic trial synopsis. Updated 2020. Accessed June 23, 2023. https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis .

17. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020; 20(8):e192–e197. PMID: 32539990.

18. Lee H, Sung HK, Lee D, Choi Y, Lee JY, Lee JY, et al. Comparison of complications after coronavirus disease and seasonal influenza, South Korea. Emerg Infect Dis. 2022; 28(2):347–353. PMID: 35076368.

19. Başcı S, Ata N, Altuntaş F, Yiğenoğlu TN, Dal MS, Korkmaz S, et al. Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers. Intern Emerg Med. 2022; 17(1):135–139. PMID: 34110562.

20. Russell B, Moss CL, Shah V, Ko TK, Palmer K, Sylva R, et al. Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in London. Br J Cancer. 2021; 125(7):939–947. PMID: 34400804.

21. Shin DW, Sunwoo S, Lee J. Management of cancer survivors in Korea. J Korean Med Assoc. 2015; 58(3):216–226.

22. Yang YS, Kimm H, Jung KJ, Moon S, Lee S, Jee SH. Prediction of cancer survivors’ mortality risk in Korea: a 25-year nationwide prospective cohort study. Epidemiol Health. 2022; 44:e2022075. PMID: 36108669.

23. National Cancer Center. Management of Cancer Survivors. Goyang: National Cancer Center;2015.

24. Trends in the prevalence of current cigarette smoking, 2012–2021. Public Health Wkly Rep. 2023; 16(20):632–633.

25. He Y, He Y, Hu Q, Yang S, Li J, Liu Y, et al. Association between smoking and COVID-19 severity: a multicentre retrospective observational study. Medicine (Baltimore). 2022; 101(29):e29438. PMID: 35866793.

26. Mohsin FM, Tonmon TT, Nahrin R, Tithy SA, Ame FA, Ara I, et al. Association between smoking and COVID-19 severity: evidence from Bangladesh. J Multidiscip Healthc. 2021; 14:1923–1933. PMID: 34326643.

27. Wook Shin D, Young Kim S, Cho J, Kook Yang H, Cho B, Nam HS, et al. Comparison of hypertension management between cancer survivors and the general public. Hypertens Res. 2012; 35(9):935–939. PMID: 22534522.

28. Gallo G, Calvez V, Savoia C. Hypertension and COVID-19: current evidence and perspectives. High Blood Press Cardiovasc Prev. 2022; 29(2):115–123. PMID: 35184271.

29. Chun JY, Kim SI, Park EY, Park SY, Koh SJ, Cha Y, et al. Cancer patients’ willingness to take COVID-19 vaccination: a nationwide multicenter survey in Korea. Cancers (Basel). 2021; 13(15):3883. PMID: 34359783.

30. Romero Starke K, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021; 6(12):e006434.

31. Kofahi HM, Swedan SF, Khabour OF, Nimer RM. Predictors of COVID-19 severity and hospitalization: a survey-based study from Jordan. Inform Med Unlocked. 2022; 31:100994. PMID: 35722635.

32. Arceo-Gomez EO, Campos-Vazquez RM, Esquivel G, Alcaraz E, Martinez LA, Lopez NG. The income gradient in COVID-19 mortality and hospitalisation: an observational study with social security administrative records in Mexico. Lancet Reg Health Am. 2022; 6:100115. PMID: 34778865.

33. Kim YY, Choe YJ, Kim J, Kim RK, Jang EJ, Lee H, et al. Vaccine effectiveness against severe disease and death for patients with COVID-19 during the delta-dominant and omicron-emerging periods: a K-COVE Study. J Korean Med Sci. 2023; 38(11):e87. PMID: 36942395.

34. Tang L, Wu J, Li CG, Jiang HW, Xu M, Du M, et al. Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia. Clin Cancer Res. 2020; 26(7):1763–1772. PMID: 31911547.

35. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020; 26(4):453–455. PMID: 32284614.

36. Pivonello R, Auriemma RS, Pivonello C, Isidori AM, Corona G, Colao A, et al. Sex disparities in COVID-19 severity and outcome: are men weaker or women stronger? Neuroendocrinology. 2021; 111(11):1066–1085. PMID: 33242856.

37. Mjaess G, Karam A, Aoun F, Albisinni S, Roumeguère T. COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. Prog Urol. 2020; 30(10):484–487. PMID: 32620366.

38. Chakravarty D, Nair SS, Hammouda N, Ratnani P, Gharib Y, Wagaskar V, et al. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun Biol. 2020; 3(1):374. PMID: 32641750.